Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NDMA OTC labeling "feedback" request

This article was originally published in The Tan Sheet

Executive Summary

Denied, FDA tells the trade association in a June 10 letter. "We are aware of your concerns and previously met on May 8, 1997, June 27, 1997, July 14, 1997 (NDAC meeting), and Sept. 30, 1997 to discuss NDMA's concerns and views on various OTC labeling issues. In addition, we extended the comment period for the proposed rule until Oct. 6, 1997, to allow NDMA and others additional time to adequately address the proposed rule," FDA says. "We do not need further clarification of your views and, thus, we do not consider another meeting necessary at this time." NDMA had wanted to discuss modifying the proposed labeling format and a package size exemption further. FDA published the proposed rule Feb. 27, 1997 ("The Tan Sheet" March 3, 1997, pp. 1-9). FDA also denies the same request from CTFA...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel